论著 Original Article

克唑替尼在ALK阳性中晚期非小细胞肺癌中的疗效观察

Published at: 2016年第36卷第5期

朱礼阳 1 , 许春伟 2 , 于忠和 1
1 安徽医科大学北京军区总医院临床学院肿瘤科,北京 100700
2 军事医学科学院附属医院病理科,北京 100071
通讯作者 忠和 于 Email: 773080192@qq.com
DOI: 10.3978/j.issn.2095-6959.2016.05.005
基金:
国家自然科学基金 81372489
北京市科技计划课题 2131100006813032
军事医学科学院附属医院创新科研基金项目 ZH-2014-10

摘要

目的:探讨克唑替尼治疗晚期间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因阳性中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的近期疗效及毒副反应。方法:回顾性分析43例ALK阳性的中晚期NSCLC患者,服用克唑替尼治疗,服用至病情进展或出现不可耐受的毒副反应,随访12个月,观察疗效。结果:克唑替尼治疗ALK阳性NSCLC的疾病控制率(disease control rate,DCR)为93%(3/43),客观缓解率(objective response rate,ORR)为62%(26/43),中位无进展生存时间(progression free survival,PFS)为7.0个月(95% CI,6.0~8.0月),不良反应主要为消化道症状,其次是谷丙转氨酶升高,视觉障碍,大部分为1~2级。结论:克唑替尼作为NSCLC患者的多靶点靶向治疗,具有良好的疗效及安全性,不良反应轻微。


Efficacy of crizotinib in advanced ALK positive non-small cell lung cancer

Abstract

Objective: To explore clinical efficacy and side effects of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. Methods: Retrospectively analysed 43 cases of ALK positive NSCLC patients, receiving oral treatment with crizotinib (250 mg) twice daily until the progress of the disease or the emergence of the side effects. Clinical efficacy was observed after 12-month followed-up. Results: The DCR of the patients treated with crizotinib was 93% (3/43), ORR was 62% (26/43), and median PFS was 7.0 months (95% CI, 6.0~8.0 months). The most frequent treatment-related AEs were gastrointestinal disturbance, followed by increased glutamic-pyruvic transaminase, vision disorder, and most toxicities were grade 1 and 2. Conclusion: Crizotinib, as targets for NSCLC patients with targeted therapy, has good effect and safety, minor adverse reactions.


comments powered by Disqus

全文

引用

引用本文: 礼阳 朱, 春伟 许, 忠和 于. 克唑替尼在ALK阳性中晚期非小细胞肺癌中的疗效观察[J]. 临床与病理杂志, 2016, 36(5): 554-558.
Cite this article as: ZHU Liyang, XU Chunwei, YU Zhonghe . Efficacy of crizotinib in advanced ALK positive non-small cell lung cancer[J]. Journal of Clinical and Pathological Research, 2016, 36(5): 554-558.